Abstract:Key PointsMany cell cycle proteins are overexpressed or overactive in human cancers, in particular, D-type and E-type cyclins, cyclin-dependent kinases (CDK4, CDK6 and CDK2), Polo-like kinase 1 (PLK1) and Aurora kinases (Aurora A and Aurora B). In transgenic mice, overexpression of several of these cell cycle proteins induces or contributes to tumorigenesis, revealing their prominent oncogenic roles.Some of these cell cycle proteins are also required for tumorigenesis, and their ablation in mice impairs tumour formation induced by specific genetic lesions or by carcinogen treatment, as demonstrated for several cyclins (D1, D2 and D3) and CDKs (CDK4, CDK6, CDK2 and CDK1), as well as for checkpoint kinase 1 (CHK1). Importantly, in some cases the continued presence of a cell cycle protein has also been shown to be required for tumour maintenance and progression, for example, for cyclin D1, cyclin D3 and CDK4, thereby providing a clear rationale for targeting these proteins in cancer treatment.Kinases involved in cell cycle checkpoint function such as CHK1 and WEE1 also constitute potential therapeutic targets. Their inhibition compromises checkpoint function, causes excessive DNA damage and eventually leads to apoptosis, particularly in cells with compromised p53 function.CDK4/6-selective inhibitors, such as palbociclib, ribociclib and abemaciclib, have shown significant benefits in clinical studies, particularly in breast cancer, but also in non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma. Importantly, following demonstration of a substantial improvement in progression-free survival, combination of palbociclib and letrozole received accelerated approval for first-line treatment of patients with advanced ER+HER2− breast cancer.Inhibitors of PLK1, such as rigosertib and volasertib, have also shown encouraging results in clinical phase II/III studies for patients with myelodysplastic syndromes and acute myelogenous leukaemia, respectively, and several phase III trials are currently ongoing.Compounds targeting Aurora A, particularly alisertib, have been extensively studied in preclinical models and demonstrated synergy with many other targeted therapies, leading to tumour regression in various cancer models. Moreover, clinical studies revealed encouraging activity of alisertib in peripheral T cell lymphoma, non-Hodgkin lymphoma, non-small-cell lung cancer and breast cancer.

CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

CDK1 Promotes Nascent DNA Synthesis and Induces Resistance of Cancer Cells to DNA-damaging Therapeutic Agents.

Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Knockdown of Cyclin D1 Inhibits Proliferation, Induces Apoptosis, and Attenuates the Invasive Capacity of Human Glioblastoma Cells

PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues

Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.

Antagonizing CDK8 Sensitizes Colorectal Cancer to Radiation Through Potentiating the Transcription of E2f1 Target Gene Apaf1

Cyclin-dependent Kinase Inhibitor 1A Inhibits Pyroptosis to Enhance Human Lung Adenocarcinoma Cell Radioresistance by Promoting DNA Repair

Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells

CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition

Development of Cell-Cycle Inhibitors for Cancer Therapy

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

Association of Protein Kinase CK2 Inhibition with Cellular Radiosensitivity of Non-Small Cell Lung Cancer

Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer

Cell cycle proteins as promising targets in cancer therapy

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

CDK inhibitors in cancer therapy, an overview of recent development